Hem › Akut bifentypisk leukemi › Oklahoma › Oklahoma City
Kliniska studier för Akut bifentypisk leukemi i Oklahoma City, OK
3 studier för Akut bifentypisk leukemi söker deltagare vid platser i och runt Oklahoma City (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
RekryterarFas 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
RekryterarFas 3
- University of Oklahoma Health Sciences Center, Oklahoma City
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekryterarFas 1/2
- University of Oklahoma Health Sciences Center, Oklahoma City
Akut bifentypisk leukemi-studier i andra städer
- Seattle, WA15 studier
- Houston, TX11 studier
- New York City, NY10 studier
- Atlanta, GA9 studier
- Durham, NC8 studier
- Memphis, TN7 studier
- Chicago, IL7 studier
- Charlotte, NC6 studier
- Baldwin Park, CA6 studier
- Aurora, CO6 studier
- Dallas, TX6 studier
- Philadelphia, PA6 studier
Andra studier i Oklahoma City
- Icke-småcellig lungcancer28 studier
- Äggstockscancer28 studier
- Endometriecancer25 studier
- Kolorektal cancer22 studier
- Prostatacancer21 studier
- Lungcancer19 studier
- Bröstcancer17 studier
- Metastaserande cancer16 studier
- Cancer (alla typer)14 studier
- Akut myeloid leukemi14 studier
- Plattenepitelcancer i huvud och hals13 studier
- Blåscancer11 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.